Abbott may sell off older drugs

SHARE Abbott may sell off older drugs

Abbott Laboratories might sell off a group of its older drugs possibly worth more than $5 billion. The North Chicago-based drugmaker is working with Morgan Stanley to find a buyer, Reuters reports. The off-patent drugs bring in about $2 billion a year in revenue. Abbott and Morgan Stanley declined to comment. Some of Abbott’s larger competitors are also looking to sell their own line-ups of legacy drugs, such as Merck & Co. and Pfizer Inc., to focus on high-growth areas.

Abbott split into two companies at the end of 2012. Abbott kept the nutritional drinks for infants and adults, generic drugs, diagnostic tests and medical devices. AbbVie, the other company, is in the high-margin but riskier business of pharmaceutical research.

Abbott Laboratories beats 1Q profit estimates

Layoffs at Abbott Laboratories: report

via Reuters

The Latest
Amid calls to fire Officer Enrique Delgado Fernandez and Sgt. Jerald Wallace in the wake of the video release, the Sun-Times has found they’ve faced dozens of investigations into their on-duty conduct.
Al menos tres autobuses llenos de migrantes recién llegados fueron dejados en una antigua escuela del lado sur que ha sido transformada en refugio. Dos manifestantes intentaron impedir que un autobús llegara a su destino.
Selvin Argueta y su hijo, que ahora tiene 21 años, dijeron que no quieren que ninguna otra familia pase por lo que ellos vivieron.
La Oficina de Protección Estudiantil y el Título IX está investigando el incidente, y el miembro del personal involucrado ha sido destituido durante la investigación.
They want to remember how he played, not how he treated his wives. It’s not a good look.